Are Americans the worst patients in the world?

That’s the question David Freedman tried to answer in an article in The Atlantic, pointing out that the high cost of the U.S. healthcare system could come down to the patients themselves.

Namely, the actions of American patients––from not following through on their care plans, getting regular checkups or engaging in community wellness––are driving up healthcare costs and would likely drive up spending under the health systems of other comparable nations.

What patients do matters much more than what healthcare providers do, according to experts. Nearly 75% of the variation in life expectancy in the U.S. is explained by lifestyle choices, such as smoking and inactivity, Freedman stated, noting a JAMA Internal Medicine study.

In addition, Americans are often overtreated, he argued, contributing to overall higher costs. When they are treated, American patients have a “flagrant disregard” for routine care and fail to take prescription drugs as prescribed.

“Marveling at what other systems around the world do differently, without considering who they’re doing it for, is madness,” Freedman wrote. “The American healthcare system has problems, yes, but those problems don’t merely harm Americans—they are caused by Americans.”

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.